IIL-Griffith Univ Readying Reasonably Priced COVID-19 Vaccine
Vaccine Launch Expected In 18-24 Months
Executive Summary
The entry of India’s state-owned Indian Immunologicals and partner Griffith University in the COVID-19 vaccine race could potentially disrupt pricing dynamics. The alliance is developing a live-attenuated, single dose vaccine, which it hopes will be ready for launch in 18-24 months.
You may also be interested in...
J&J, Pfizer, Russian COVID-19 Vaccines Set For Indian Approval In '21
Multiple COVID-19 vaccines, including from J&J, Pfizer and RDIF, are seen gaining approvals in India in 2021, following on from a raft of R&D, manufacturing and marketing tie-ups, as well as other developments, in the action-packed field last year.
Coronavirus Update: FDA Fast-Tracks Blood Plasma Trials, Novavax Closes In On Vaccine Start
As US cases set to reach half a million, FDA gives green light to blood plasma trials to help meet urgent need for therapies.
Moderna Stands Alone With Single-Antigen Approach To COVID-19 Vaccine
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Need a specific report? 1000+ reports available
Buy Reports